Equillium, Inc. (EQ)

Over the past six months, Equillium's stock price has trended upwards. In May 2026, inducement grants were reported, and the company participated in Oppenheimer's 2026 Innovation on the Island Event. In April 2026, poster presentations were announced at IMMUNOLOGY2026™, and SEC filings indicated a stake by Aberdeen Group, an effectiveness order, an annual report, and a proxy statement regarding a reverse split and share increase. B.Riley, Raymond James, Roth/MKM, and Stifel initiated coverage with positive ratings. In March 2026, Equillium reported its Fourth Quarter and Full Year 2025 financial results, including no revenue in 2025, a net loss, and the completion of a private placement, and participated in the 38th Annual Roth Conference. In November 2025, the company discussed Aryl Hydrocarbon Receptor as a Drug Target and the EQ504 Program in Immune-Mediated Diseases.

Equillium exhibits some demand seasonality based on historical stock price data. May has a high probability of positive returns, while October has the lowest probability.

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders. The company operates in the Healthcare sector, specifically in the Biotechnology industry, focusing on pharmaceutical preparation manufacturing. Equillium's pipeline includes immunomodulatory assets such as EQ504, Itolizumab (EQ001), EQ302, and EQ101.

Equillium, Inc. is headquartered in La Jolla, California, United States. The company primarily develops therapeutics for the United States market and aims for global market expansion through strategic partnerships and collaborations.

Equillium's brand reputation is influenced by its clinical development progress and financial activities. Analyst firms have shown growing interest with positive ratings, while Weiss Ratings maintains a negative rating. The stock's performance has seen significant gains, which can positively impact reputation among investors. However, a previous event where itolizumab treatment failed to show improvement in response rates in Graft Versus Host Disease patients, despite improved longer-term outcomes, could have temporarily impacted perception. Shareholders have also experienced substantial dilution in the past year.

Equillium, Inc. has institutional owners and shareholders holding a significant percentage of the stock. Major institutional shareholders include Janus Henderson Group Plc, ADAR1 Capital Management, LLC, Adage Capital Partners Gp, L.l.c., Decheng Capital LLC, Woodline Partners LP, Standard Life Aberdeen plc, Balyasny Asset Management Llc, Vanguard Group Inc, Takeda Pharmaceutical Co Ltd, and Renaissance Technologies Llc. Other significant institutional holders include RA Capital Management, L.P. and State Street Global Advisors, Inc. Individual insiders also hold a portion of the shares.